Filtered By:
Specialty: Cardiology
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 800 results found since Jan 2013.
The endothelial-enriched lncRNA LINC00607 mediates angiogenic function
In conclusion,LINC00607 is an endothelial-enriched lncRNA that maintains ERG target gene transcription by interacting with the chromatin remodeler BRG1 to ultimately mediate angiogenesis.
Source: Basic Research in Cardiology - January 26, 2023 Category: Cardiology Source Type: research
Can siRNA Improve Compliance in Patients With Hypertension? Can siRNA Improve Compliance in Patients With Hypertension?
Patients achieve a reduction in systolic blood pressure of>15 mm Hg for as long as 8 weeks after administration of a single dose of zilebesiran.Medscape Medical News
Source: Medscape Cardiology Headlines - January 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Gene editing for dyslipidemias: New tools to “cut” lipids
Effective lipid lowering therapies are essential for the prevention of atherosclerosis and cardiovascular disease. Available treatments have evolved in both their efficacy and their frequency of administration, and currently include monoclonal antibodies, ASO and siRNA approaches. However, an unmet need remains for more effective and long-lasting therapeutics. Gene editing permanently alters endogenous gene expression and has the potential to revolutionize disease treatment. Despite the existence of several gene editing approaches, the CRISPR/Cas9 system has emerged as the preferred technology because of its high efficienc...
Source: Atherosclerosis - January 13, 2023 Category: Cardiology Authors: Sylvia Stankov, Marina Cuchel Tags: Review article Source Type: research
A Novel Angiogenic Effect of PCSK9- Regulated Genes
CONCLUSION: PCSK9 might play an essential role in angiogenesis, unlike its typical role in lipid metabolism, and MMP9, Caspase3, LEFTY1, NODAL, and EGR1 may be involved in the regulation of angiogenesis as critical genes.PMID:36427678 | DOI:10.1016/j.gene.2022.147051
Source: Atherosclerosis - November 25, 2022 Category: Cardiology Authors: Xiaopeng Zhan Li Jiang Lufeng Wang Jiwen Liu Sheng Kang Haibo Liu Li Lin Source Type: research
siRNA therapy markedly reduces Lp(a) levels
Nature Reviews Cardiology, Published online: 16 November 2022; doi:10.1038/s41569-022-00813-7Olpasiran, a small interfering RNA (siRNA) that reduces lipoprotein(a) (Lp(a)) production in the liver, administered every 12 weeks induces a pronounced and sustained decrease in the plasma levels of Lp(a) in patients with established atherosclerotic cardiovascular disease, according to findings from the OCEAN(a)-DOSE trial.
Source: Nature Reviews Cardiology - November 16, 2022 Category: Cardiology Authors: Irene Fern ández-Ruiz Source Type: research
Trichostatin D as a Novel KLF2 Activator Attenuates TNF α-Induced Endothelial Inflammation
Int J Mol Sci. 2022 Nov 3;23(21):13477. doi: 10.3390/ijms232113477.ABSTRACTKrüppel-like factor 2 (KLF2) is an atherosclerotic protective transcription factor that maintains endothelial cell homeostasis through its anti-inflammatory, anti-oxidant, and antithrombotic properties. The aim of this study was to discover KLF2 activators from microbial secondary metabolites and explore their potential molecular mechanisms. By using a high-throughput screening model based on a KLF2 promoter luciferase reporter assay, column chromatography, electrospray ionization mass spectrometry (ESI-MS), and nuclear magnetic resonance (NMR) spe...
Source: Atherosclerosis - November 11, 2022 Category: Cardiology Authors: Lijuan Lei Minghua Chen Chenyin Wang Xinhai Jiang Yinghong Li Weizhi Wang Shunwang Li Liping Zhao Ren Sheng Jiangxue Han Yuyan Zhang Yuchuan Chen Biying Yan Yexiang Wu Liyan Yu Shuyi Si Yanni Xu Source Type: research
PCSK9 Knockdown Can Improve Myocardial Ischemia/Reperfusion Injury by Inhibiting Autophagy
This study investigates the effect and mechanism of proprotein convertase subtilisin/Kexin type 9 (PCSK9) on myocardial ischemia-reperfusion injury (MIRI) and provides a reference for clinical prevention and treatment of acute myocardial infarction (AMI). We established a rat model of myocardial ischemia/reperfusion (I/R) and AC16 hypoxia/reoxygenation (H/R) model. A total of 48 adult 7-week-old male Sprague-Dawley rats were randomly assigned to three groups (n = 16): control, I/R, and I/R + SiRNA. In I/R and I/R + siRNA groups, myocardial ischemia was induced via occlusion of the left anterior descending branch (LAD) of t...
Source: Cardiovascular Toxicology - November 7, 2022 Category: Cardiology Authors: Guangwei Huang Xiyang Lu Zonggang Duan Kai Zhang Lei Xu Hailong Bao Xinlin Xiong Muzhi Lin Chao Li Yunquan Li Haiyan Zhou Zhenhua Luo Wei Li Source Type: research
PCSK9 inhibition might increase endothelial inflammation
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) has been discovered as the nineth member of an autocatalytic serine protease family [1]. Soon afterwards, it could be demonstrated that mutations of this gene are associated with certain types of familial hypercholesterolemia suggesting a role in cholesterol metabolism [2]. Further studies revealed that overexpression of PCSK9 is actually elevating cholesterol levels in the blood concomitant with a downregulation of LDL-receptors (LDLRs) [3,4] and that siRNA-mediated knockdown increases LDL-receptor surface levels leading to enhanced cholesterol uptake in cultured cells [4].
Source: Atherosclerosis - November 7, 2022 Category: Cardiology Authors: Johannes A. Schmid Tags: Editorial Source Type: research
Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease
J Clin Lipidol. 2022 Oct 20:S1933-2874(22)00289-6. doi: 10.1016/j.jacl.2022.10.004. Online ahead of print.ABSTRACTThe role of lipoprotein(a) (Lp[a]) as a significant and possibly causal cardiovascular disease (CVD) risk factor has been well established. Many studies, mostly experimental, have supported inflammation as a mediator of Lp(a)-induced increase in CVD risk. Lp(a), mainly through oxidized phospholipids bound to its apolipoprotein(a) part, leads to monocyte activation and endothelial dysfunction. The relationship between Lp(a) and inflammation is bidirectional as Lp(a) levels, besides being associated with inflamma...
Source: Atherosclerosis - November 4, 2022 Category: Cardiology Authors: Spyridon Simantiris Alexios S Antonopoulos Charalampos Papastamos Georgios Benetos Nikolaos Koumallos Konstantinos Tsioufis Dimitris Tousoulis Source Type: research
PRC2-dependent regulation of ganglioside expression during dedifferentiation contributes to the proliferation and migration of vascular smooth muscle cells
In this study, we sought to reveal the endogenous expression of gangliosides and their functional significance in VSMCs during atherosclerosis. We found that switching from the contractile to proliferative phenotype was accompanied by upregulation of a- and b-series gangliosides, which in turn, were regulated by polycomb repressor complex 2 (PRC2). Downregulation of ganglioside expression using an siRNA targeting ST3GAL5, which is required for the synthesis of a- and b-series gangliosides, attenuated the proliferation and migration of dedifferentiated VSMCs. Therefore, we concluded that the increased expression of a- and b...
Source: Atherosclerosis - October 31, 2022 Category: Cardiology Authors: Norihiko Sasaki Kazumi Hirano Yuuki Shichi Yoko Itakura Toshiyuki Ishiwata Masashi Toyoda Source Type: research
Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition augments recirculation of the low-density lipoprotein (LDL) receptor to the hepatocyte surface [1], thereby lowering atherogenic particles through accelerated clearance of circulating LDL cholesterol (LDL-C). This observation led to several strategies to inhibit PCSK9, including monoclonal antibodies (evolocumab and alirocumab), small-molecule inhibitors specific to PCSK9, small interfering RNA (siRNA) molecules (inclisiran), antisense oligonucleotides, immunotherapy with a PCSK9 peptide vaccine, and CRISPR/Cas9 editing of PCSK9.
Source: Atherosclerosis - October 21, 2022 Category: Cardiology Authors: Maya S. Safarova, Iftikhar J. Kullo Tags: Editorial Source Type: research
